--
--(--)
--
--(--)
Expected P&L on Expiry
Key Stats
0.00DAY`S RANGE0.00
0.00
0.00
--
--
--
--
--
--
--
Pricing Model
--
--
--
--
--
--
About ALDX20260417C2
Pharmaceutical
Aldeyra Therapeutics, Inc., was incorporated in Delaware on August 13, 2004. The company is a clinical-stage biotechnology company dedicated to the discovery and development of innovative therapies designed to treat immune-mediated diseases. Its approach focuses on regulating the protein system, and late-stage drug candidates include reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for retinal diseases.
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
